Search results
Results from the WOW.Com Content Network
Neurocrine Biosciences exceeded earnings expectations for Q4 2024, ... Yahoo Sports. Steelers to host international game in Dublin, marking first NFL game in Ireland.
California-based biopharmaceutical company Neurocrine Biosciences reported worse-than-expected earnings in the fourth quarter as sales disappointed on anticipated inventory destocking; however ...
Neurocrine Biosciences Inc’s (NASDAQ:NBIX): Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in ...
The update presented by Neurocrine included the following information: An End of Phase 2 meeting for NBI-1117568 (NBI-’568, an oral, muscarinic M4 selective agonist) has been completed with the US Food & Drug Administration and Neurocrine reiterated its intentions to begin Phase 3 registrational studies in schizophrenia in 1H 2025.
Neurocrine received upfront fees and early milestone payments totaling $25.5 million. [13] In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. [14] [15] The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales ...
Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another ...
November: The rights were then transferred to Neurocrine Biosciences, which took over the development of NBI-1117568. [11] 2022 October: Phase II clinical trials began for NBI-1117568 to treat schizophrenia. [12] 2024 April: Neurocrine Biosciences announced that NBI-1117568 had met the requirements of long-term preclinical toxicity tests. [13]